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JLGTD Editorial   
Core outcome sets for Clinical trials and Observational Studies in Vulvovaginal Disease 
I. Define the issue—general concepts 
Clinical trials and observational studies in medical research have been criticized for lack of clearly 
defined, well-validated, reliable, and responsive outcome measures resulting in poor reproducibility 
and difficulty with cross-comparison of studies.  Additionally, outcome assessment can vary greatly 
based upon the specific “stakeholder” involved (i.e. patient, medical researcher, practitioner, or 
healthcare payer). The collective recognition of the need for consensus in research outcomes 
methodology has spurred a number of major initiatives including but not limited to: Patient-Reported 
Outcomes Measurement Information System (PROMIS)1, Initiative on Methods, Measurement, and 
Pain Assessment in Clinical Trials (IMMPACT)2, Outcome Measures in Rheumatology (OMERACT)3, 
and Harmonizing Outcome Measures for Eczema (HOME).4  In addition to providing standard, 
condition-specific research guidelines, these initiatives provide excellent roadmaps for research 
methodology improvement in other health care fields.  A recent ‘call-to-action’ in the field of women’s 
health known as the Core Research Outcomes in Women's and Newborn health (CROWN) initiative 
has been endorsed by a substantial group of professional journals focused on women’s health issues, 
including the Journal of Lower Genital Tract Disease.5;6     
II. Define the issue—specific to vulvovaginal disease 
 
Evidence-based practice lags behind in this field, particularly when compared with other disciplines in 
women’s health. The development of interventional clinical trials for vulvovaginal conditions is 
hampered by the lack of essential information required to inform trial design, including validated 
outcome measures that can be recommended for a core outcome set. As a result, many published 
randomised studies are heterogeneous, of poor methodological quality and difficult to combine in 
metaanalysis, meaning that they cannot be utilised to inform evidence based practice.  
Other more “developed” disciplines in women’s health such as gynecologic oncology, reproductive 
endocrinology, and maternal-fetal medicine have evolved productive research directions.  Research in 
these disciplines has been facilitated through subspecialty development, preferential research funding, 
and a perception of significant societal impact from the respective disease states. In contrast, well-
designed, vulvovaginal clinical trials and observational studies, such as in vulvodynia, lichen sclerosus 
and mucosal / erosive lichen planus, are relatively small in number.7-9 In spite of the research neglect, 
vulvovaginal disorders fall within the top ten ambulatory visits by women and lead to multiple return 
visits, development of sexual dysfunction, progression of chronic pain, and a negative impact on 
overall quality-of-life10.  Clinically, many vulvovaginal complaints are infrequently raised by patients in 
discussion with the healthcare provider, based on devastating biopsychosexual implications that 
results in a ‘suffering-in-silence’.11    
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III. What is a core outcome set (COS) and a domain?   
A core outcome set is a minimum set of outcomes for all clinical trials of a particular condition/group 
of conditions and will enable trials to be compared in meta-analyses. Core outcome sets consist of 
measures of effectiveness that are relevant to patients, care providers, and all other stakeholders.  
 ‘Outcome domains’ are distinct elements of a disease (including consequence of the disease) 
such as patient defined symptoms, physician defined signs, laboratory assessments including 
histopathology, duration of effect of treatment and quality-of-life.    
 Outcome measures are  ‘instruments’ that measure the domains.(Schmitt 2015) 
There is a lack of consensus with regard to the selection of outcomes for clinical trials.12 As a result, 
different outcomes are assessed  in different trials on the same population and intervention, important 
outcomes are missed by many trials, and/or different ways of measuring the same outcome domain 
are used, causing inconsistencies in reporting and difficulties in comparing and combining the findings 
in systematic reviews and meta-analyses and eventually using (pooled) trial information for clinical 
decision making. Consensus-based COS development is key to improvement of observational 
research and clinical trial methods by facilitating multicenter collaboration, providing reproducible 
measures of outcomes (i.e. drug testing results, disease status changes, etc.), and strengthening 
between-study comparisons such as meta-analyses. Formally defined structure such as Delphi panels 
can provide the essential foundation for the construction of widely accepted core outcome sets.13   
Core outcome sets should address the following points:    
 Usually consist of measures of effectiveness or harm 
 Relevant to patients and care providers 
 Relevant to those making decisions about health care cost-effectiveness  
 Need to be valid, reliable, responsive to change  
 Easy to implement  
 Core outcomes may be different for clinical trials and routine care 
 Some core outcomes may be generalizable to a wide spectrum of conditions while other core 
outcomes may be disease-specific 
Core outcome domains may cover: 
 (patient-reported) symptoms 
 (clinician-reported) signs 
 quality of life  
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Examples of "instruments" that measure single items or measures of defined domains of a COS  for 
vulvovaginal disease include: 
 Quality of life indices 
 Female Sexual Functioning Index14 
 Patient Global Assessment of symptoms 
 Visual Analog Scale (VAS) for daily pain or itch level 
 Tampon Test for vulvodynia15 
 Vaginal maturation index 
 Physician’s global assessment of signs 
 Biopsy for histopathological investigation 
It is important to realise that core outcomes are not necessarily the only outcomes to be included in a 
trial. Other outcomes in addition to the core outcomes may be included to suit the needs of each 
particular trial. Core outcomes do not necessarily need to be the primary trial outcomes. 
IV. Organization is needed for ongoing independent workgroups  
Based on a collective recognition of need, a number of workgroups have begun to address improved 
outcomes research in vulvovaginal disorders. However, the ongoing initiatives lack a unified focus and 
integration of efforts.   Inevitably, the various workgroups will uncover common ground with respect to 
sexual dysfunction, chronic pain / itching, emotional disorders such as depression, and quality-of-life 
experience.  Diverse diagnoses such as vulvodynia, lichen sclerosus, erosive lichen planus, recurrent 
vulvovaginal candidiasis, and vaginal atrophy will be found to be connected, based on blurred 
diagnostic boundaries or linked disease relationships. There is, therefore, need for a unified, focused, 
integrated consensus effort.   
V. Proposal: Development of a broad-based COS for vulvovaginal disease (VVD)  
In spite of the relatively broad range of conditions encountered by specialists in the field, several 
factors argue for COS development that will span the spectrum of disease affecting the female lower 
genital tract:  
 The diagnostic hallmarks of many vulvovaginal conditions, such as vulvodynia, lichen 
sclerosus, vaginal atrophy, and recurrent vulvovaginal candidiasis, are unclearly defined and 
are often coexisting.    
 Diverse vulvovaginal afflictions promote a common psychosexual impact on the afflicted 
patient.  This encourages a common assessment of patient reported quality-of-life outcomes 
across a spectrum of disorders.  
 Developmentally, the three closely juxtaposed embryologic derivatives, making up the female 
lower genital tract may lead to confusing differences in tissue behavior within an anatomically 
unified region.16   A classic example of physiologic variation based upon embryologic origin is 
seen in the difference in estrogen responsiveness between the vagina and vulvar vestibule.   
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The primary goal of a vulvovaginal disease COS initiative would be to develop consensus opinion 
concerning common domains and outcome measure instruments for vulvovaginal disorders.  
Publication of these consensus opinions would provide well defined, concrete direction for future 
research in the field.   
We propose defining core domains, and identifying 
vulvovaginal disease COS and outcome assessment 
instruments that focus on at least three vulvovaginal 
disease subject areas: 
 Vulvar inflammatory Dermatoses   
 Vulvar Pain States (Vulvodynia) 
 Vaginitis (Infectious (and non-infectious))  
The vulvovaginal disease COS initiative should remain 
relatively broad in scope of medical conditions, be internationally-based, involve a broad stake holder 
group, and utilize recognized consensus methods such as Delphi panels and patient-centered focus 
groups.   
 
VI. The initial roadmap of COS development 
Prior expert panel consensus initiatives such as IMMPACT2 provide a clear roadmap for development 
of a series of major meetings covering all vulvovaginal COS areas and focused on three goals:  1) 
Delimiting clinical conditions and identifying core domains within each condition, 2) Identifying and 
defining core outcomes / instruments, and 3) Development of clinical research structure for 
randomized clinical trials (RCTs) in the respective subject areas.   Core domains, such as sexual 
dysfunction and pain, would span all vulvovaginal conditions. Additional area-specific domains such 
as ‘dermatologic architectural change’ and ‘laboratory assessment of vaginal milieu’ would also be 
developed.  Publication of internationally accepted core outcome measures for clinical trials and 
observational studies would enable the synthesis of evidence-based practice by facilitating cross-
comparison and meta-analysis of studies. 
Further points in COS development: 
 Language / cultural issues:  The vulvovaginal COS initiative should provide similar patient-
directed measures across cultures and languages. Stakeholders must be internationally-based, 
including public, medical researchers, health care professionals, and health care policy experts 
with a global perspective.  This will require appropriate translation. Cultural response 
differences will likely be recognized requiring alteration of measurement tools.  PROMIS 
guidelines1 will provide important direction in this instance.   
 HPV associated / neoplastic disease: Updated consensus guidelines are in process of 
development and publication by a dedicated expert panel.  HPV associated disease, therefore, 
will not be covered in this initiative.  Future integration of COS for genital neoplasia will likely 
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 Relationship to clinical recommendations: This effort will be focused on a minimum set of 
core outcomes (COS) for research and should not be misinterpreted as clinical guidelines.  
Application to clinical practice, also known as clinical practice guidelines, will follow improved 
clinical research methodology and performance of appropriate clinical trials.   
 Publication of standards for performance of clinical trials research in lower genital tract 
disorders:  The Journal of Lower Genital Tract Disease (JLGTD) would facilitate a forum of 
discussion on COS development.  Publications would necessarily undergo standard peer-
review process but could develop a facilitated review process. Rapid turn-around from 
consensus meeting to publication should be ensured.  
 Continual review and update of COS should be anticipated: COS development cannot be 
considered final or static.  Rather, the concepts of outcome assessment would need regular 
review and updating based upon the existing state of the science.    
It is our intention, under the auspices of two major medical societies: the American Society for Colposcopy and 
Cervical Pathology (ASCCP) and the International Society for the Study of Vulvovaginal Disease (ISSVD), to 
provide overall direction, facilitate consensus meetings on vulvovaginal research outcomes measures, and 
publish consensus results.  The consensus meetings may take several forms including a) expert panels, b) 
Delphi programs and c) Patient centered focus groups. 
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